Research map: Comparative clinical evaluation of endothelin receptor antagonists in pulmonary arterial hypertension using a multi-criteria decision analysis framework

Back to the article

Papers in this map

  1. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension · Marc Humbert · 2022 · 3985 citations · Cited by this paper
  2. Perspectives on shared decision making related to medications from patients with multiple long-term conditions transitioning from hospital to home: a qualitative study · 2026 · Related
  3. Analytic hierarchy process: An overview of applications · Omkarprasad S. Vaidya · 2004 · 3818 citations · Cited by this paper
  4. Development of a real-world, therapeutic drug monitoring–informed model to predict teicoplanin daily dose in pediatric intensive care unit patients with bacterial infections · 2026 · Related
  5. Bosentan Therapy for Pulmonary Arterial Hypertension · Lewis J. Rubin · 2002 · 2736 citations · Cited by this paper
  6. Comment on “evaluation of high dose post-dialytic versus daily beta-lactam dosing in hemodialysis patients using Monte Carlo simulation” · 2026 · Related
  7. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study · Richard N. Channick · 2001 · 1537 citations · Cited by this paper
  8. Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System · 2026 · Related
  9. Pulmonary Arterial Hypertension · Harrison W. Farber · 2004 · 1468 citations · Cited by this paper
  10. Patient perspectives on atrial fibrillation management and pharmacist roles in outpatient clinics: a qualitative study · 2026 · Related
  11. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension · Tomás Pulido · 2013 · 1458 citations · Cited by this paper
  12. Active surveillance and risk prediction of piperacillin/tazobactam‑associated hypokalaemia: development and external validation of a clinical nomogram · 2026 · Related
  13. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension · Nazzareno Galiè · 2008 · 1092 citations · Cited by this paper
  14. Consumers’ experiences and perspectives on reporting adverse drug reactions using digital tools: a qualitative study · 2026 · Related
  15. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial · Nazzareno Galiè · 2008 · 925 citations · Cited by this paper
  16. Grounding clinical supervision in advanced pharmacy practice: a new conceptual model · 2026 · Related
  17. Bosentan Therapy in Patients With Eisenmenger Syndrome · Nazzareno Galiè · 2006 · 846 citations · Cited by this paper
  18. A multi-method study of unlicensed medicine risk assessment: a cross-sectional survey of pharmacy procurement leads and policy analysis across NHS trusts in England · 2026 · Related
  19. Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension · Xavier Jaïs · 2008 · 550 citations · Cited by this paper
  20. A qualitative exploration of healthcare professionals’ perspectives on the role of pharmacists in screening older adults for depression during medication reviews · 2026 · Related
  21. The endothelin system in pulmonary arterial hypertension · Nazzareno Galiè · 2004 · 515 citations · Cited by this paper
  22. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions · Chris Denton · 2006 · 261 citations · Cited by this paper
  23. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial · Olivier Sitbon · 2019 · 186 citations · Cited by this paper
  24. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease · Giuseppe Valerio · 2009 · 166 citations · Cited by this paper
  25. Making Good Decisions in Healthcare with Multi-Criteria Decision Analysis: The Use, Current Research and Future Development of MCDA · Axel Christian Mühlbacher · 2015 · 161 citations · Cited by this paper
  26. Fixed- and Random-Effects Models · Steve Kanters · 2021 · 153 citations · Cited by this paper
  27. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study) · Zixuan Pan · 2019 · 98 citations · Cited by this paper
  28. The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value · Steven D. Pearson · 2018 · 86 citations · Cited by this paper
  29. Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study · Sophia Emmons‐Bell · 2021 · 83 citations · Cited by this paper
  30. Cost-effectiveness analysis and incremental cost-effectiveness ratios · Kiran M. Bambha · 2004 · 75 citations · Cited by this paper
  31. Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs—a Systematic Literature Review. Next Steps in Methodology Development? · Aleksandra Baran-Kooiker · 2018 · 75 citations · Cited by this paper
  32. Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension · David B. Badesch · 2002 · 37 citations · Cited by this paper
  33. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial · Jean‐Luc Vachiéry · 2018 · 29 citations · Cited by this paper
  34. Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension · Rogério Souza · 2022 · 18 citations · Cited by this paper
  35. Can multi-criteria decision analysis (MCDA) be implemented into real-world drug decision-making processes? A Canadian provincial experience · Tracey‐Lea Laba · 2020 · 17 citations · Cited by this paper
  36. New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review · Amir Rasheed · 2024 · 10 citations · Cited by this paper
  37. Liver injury associated with endothelin receptor antagonists: a pharmacovigilance study based on FDA adverse event reporting system data · Jinjian Gu · 2024 · 6 citations · Cited by this paper
  38. Comparative Treatment Persistence and Adherence to Endothelin Receptor Antagonists Among Patients with Pulmonary Arterial Hypertension in Japan: A Real-World Administrative Claims Database Study · Junichi Omura · 2023 · 5 citations · Cited by this paper

Source: OpenAlex (CC0)